141 related articles for article (PubMed ID: 27765941)
1. Regulatory watch: Innovative drug availability in China.
Shao L; Xu L; Li Q; Chakravarthy R; Yang Z; Kaitin KI
Nat Rev Drug Discov; 2016 Nov; 15(11):739-740. PubMed ID: 27765941
[No Abstract] [Full Text] [Related]
2. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
3. Legal and regulatory developments of the 1990s in oral care products: learning from what has come before.
O'Reilly JT
J Public Health Dent; 1992; 52(6):396-400. PubMed ID: 1432936
[TBL] [Abstract][Full Text] [Related]
4. Patent watch: post-approval testing shielded from patent infringement.
Harrison C
Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 23097768
[No Abstract] [Full Text] [Related]
5. The FDA: is it protecting the public with one hand tied behind its back?
Shedlin RS
Law Med Health Care; 1992; 20(3):253-7. PubMed ID: 1434771
[No Abstract] [Full Text] [Related]
6. Recent issues regarding controlled substances.
Helgeland D
S D Med; 2013 Mar; 66(3):105, 107. PubMed ID: 23544298
[No Abstract] [Full Text] [Related]
7. Right to try?
Lieu CH; Sorkin A; Messersmith WA
J Clin Oncol; 2015 May; 33(13):1518. PubMed ID: 25779561
[No Abstract] [Full Text] [Related]
8. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
Sinha V; Zhao P; Huang SM; Zineh I
Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
[TBL] [Abstract][Full Text] [Related]
9. Regulatory watch: FDA PDUFA goals missed.
Hay M
Nat Rev Drug Discov; 2009 Jan; 8(1):10. PubMed ID: 19116619
[No Abstract] [Full Text] [Related]
10. Legislative reform proposals.
Bruderle TP
Am J Health Syst Pharm; 1996 Sep; 53(17):2083-7. PubMed ID: 8870897
[No Abstract] [Full Text] [Related]
11. Market watch: upcoming market catalysts in Q1 2012.
Inui E
Nat Rev Drug Discov; 2012 Jan; 11(1):10. PubMed ID: 22212666
[No Abstract] [Full Text] [Related]
12. Preserve the FDA's authority.
Guharoy R
Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
[No Abstract] [Full Text] [Related]
13. Drug approval: future aspects of the FDA.
Skelly JP
Methods Find Exp Clin Pharmacol; 1998; 20(6):527-37. PubMed ID: 9789876
[No Abstract] [Full Text] [Related]
14. A death by any other name: the federal government's inconsistent treatment of drugs used in lethal injections and physician-assisted suicide.
Miller C
J Law Health; 2002-2003; 17(2):217-40. PubMed ID: 15853126
[No Abstract] [Full Text] [Related]
15. Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program.
Ho C; Lim HJ; Regier DA
JAMA Netw Open; 2021 Aug; 4(8):e2120301. PubMed ID: 34379128
[TBL] [Abstract][Full Text] [Related]
16. Regulatory watch: FDA new drug approvals in Q2 2018.
Urquhart L
Nat Rev Drug Discov; 2018 Jul; 17(8):536-537. PubMed ID: 30057412
[No Abstract] [Full Text] [Related]
17. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
18. Medical Marijuana.
Capriotti T
Home Healthc Now; 2016 Jan; 34(1):10-5. PubMed ID: 26645838
[TBL] [Abstract][Full Text] [Related]
19. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
Niedelman SM
Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
[No Abstract] [Full Text] [Related]
20. Is the FDA approving drugs too fast?. Probably not--but drug recalls have sparked debate.
Kleinke JD; Gottlieb S
BMJ; 1998 Oct; 317(7163):899. PubMed ID: 9756801
[No Abstract] [Full Text] [Related]
[Next] [New Search]
